SG11201706657PA - Compounds for improving the half-life of von willebrand factor - Google Patents

Compounds for improving the half-life of von willebrand factor

Info

Publication number
SG11201706657PA
SG11201706657PA SG11201706657PA SG11201706657PA SG11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA
Authority
SG
Singapore
Prior art keywords
compounds
improving
life
von willebrand
willebrand factor
Prior art date
Application number
SG11201706657PA
Other languages
English (en)
Inventor
Michael Moses
Stefan Schulte
Gerhard Dickneite
Uwe Kalina
Sabine Pestel
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Recombinant Facility Ag filed Critical Csl Behring Recombinant Facility Ag
Publication of SG11201706657PA publication Critical patent/SG11201706657PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201706657PA 2015-03-06 2016-03-04 Compounds for improving the half-life of von willebrand factor SG11201706657PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15158088 2015-03-06
PCT/EP2016/054650 WO2016142289A1 (en) 2015-03-06 2016-03-04 Compounds for improving the half-life of von willebrand factor

Publications (1)

Publication Number Publication Date
SG11201706657PA true SG11201706657PA (en) 2017-09-28

Family

ID=52629453

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706657PA SG11201706657PA (en) 2015-03-06 2016-03-04 Compounds for improving the half-life of von willebrand factor

Country Status (12)

Country Link
US (1) US20180043012A1 (ko)
EP (1) EP3265489B1 (ko)
JP (1) JP6704420B2 (ko)
KR (1) KR20170125942A (ko)
CN (1) CN107428831A (ko)
AU (1) AU2016231328B2 (ko)
BR (1) BR112017017852A2 (ko)
CA (1) CA2978134A1 (ko)
DK (1) DK3265489T3 (ko)
ES (1) ES2755449T3 (ko)
SG (1) SG11201706657PA (ko)
WO (1) WO2016142289A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201315A1 (en) * 2020-11-24 2022-06-02 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3987114B2 (ja) * 1996-04-24 2007-10-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 不活性化耐性第▲８▼因子
US7977460B2 (en) * 2003-05-19 2011-07-12 National Institute For Biological Standards And Control Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
JP2005132796A (ja) * 2003-10-31 2005-05-26 Tatsuro Irimura 肉芽組織形成性疾患の治療のための医薬組成物および方法
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
EP2662083A1 (en) * 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
EP2669679A1 (en) * 2012-05-28 2013-12-04 Universitätsklinikum Hamburg-Eppendorf Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain
SG11201500045RA (en) * 2012-07-11 2015-02-27 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
CN113831415A (zh) * 2013-06-28 2021-12-24 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途

Also Published As

Publication number Publication date
CA2978134A1 (en) 2016-09-15
JP6704420B2 (ja) 2020-06-03
CN107428831A (zh) 2017-12-01
DK3265489T3 (da) 2019-07-15
US20180043012A1 (en) 2018-02-15
WO2016142289A1 (en) 2016-09-15
AU2016231328A1 (en) 2017-10-26
EP3265489B1 (en) 2019-05-08
EP3265489A1 (en) 2018-01-10
KR20170125942A (ko) 2017-11-15
AU2016231328B2 (en) 2018-07-05
BR112017017852A2 (pt) 2018-04-10
JP2018510213A (ja) 2018-04-12
ES2755449T3 (es) 2020-04-22

Similar Documents

Publication Publication Date Title
HK1256059A1 (zh) 新化合物
HK1243410A1 (zh) 新型化合物
GB201604647D0 (en) Novel compounds
GB201610147D0 (en) Novel compounds
GB201602854D0 (en) Novel compounds
GB201603779D0 (en) Novel compounds
GB201521109D0 (en) Novel compounds
GB201516243D0 (en) Novel compounds
GB201522768D0 (en) Novel compounds
GB201506871D0 (en) Novel compounds
GB201501462D0 (en) Novel compounds
GB201522179D0 (en) Novel compounds
EP3164150A4 (en) Modified von willebrand factor
HK1250724A1 (zh) 用於製備經修飾的血管性血友病因子的方法
GB201504565D0 (en) Novel compounds
HK1244292A1 (zh) 具有改善的半衰期的經修飾的血管性血友病因子
GB201502675D0 (en) Novel compounds
GB201601301D0 (en) Novel compounds
SG11201706657PA (en) Compounds for improving the half-life of von willebrand factor
GB201610391D0 (en) Novel compounds
GB201607931D0 (en) Novel compounds
GB201607928D0 (en) Novel compounds
GB201607922D0 (en) Novel compounds
GB201607921D0 (en) Novel compounds
GB201605059D0 (en) Novel compounds